Premium
High‐powered percutaneous microwave ablation of stage I medically inoperable non‐small cell lung cancer: A preliminary study
Author(s) -
Liu Howard,
Steinke Karin
Publication year - 2013
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/1754-9485.12068
Subject(s) - medicine , microwave ablation , ablation , pneumothorax , stage (stratigraphy) , lung cancer , percutaneous , radiology , cancer , nuclear medicine , surgery , oncology , paleontology , biology
Purpose To retrospectively evaluate the feasibility and outcome of using high‐powered percutaneous microwave ablation ( MWA ) in treating medically inoperable early stage non‐small cell lung cancer. Materials and Methods From N ovember 2010 to J une 2012, 15 patients underwent CT ‐guided MWA of 15 tumours in 16 sessions. One patient had a second ablation session for local tumour progression. Each tumour had a diameter of 40 mm or less (median 24 mm). Treatment outcome was evaluated using modified response evaluation criteria in solid tumours criteria based on follow‐up contrast‐enhanced CT studies and 18‐ F fluorodeoxyglucose positron emission tomography scans. Results Thirty‐three ablation cycles of 15 tumours were performed in 16 sessions (2.1 per session), with a median duration of 2.5 min per ablation. Treatment was completed in all cases with no 30‐day mortality. At a median follow‐up period of 1 year, local progression was identified following 5/16 (31%) ablation sessions. Eleven out of 16 (69%) of MWA s had shown local treatment response, with 9/11 displaying complete response and 2/11 displaying partial response. Local progression on follow up was predominantly seen in pleural‐based tumours that were greater than 30 mm in longest axial diameter (4/5 cases). The main adverse event was a pneumothorax, which occurred in 10/16 (63%) of procedures, but a chest tube was only required in 2/16 (13%) cases. Conclusion Percutaneous MWA in early stage non‐small cell lung cancer is well tolerated and has promising midterm outcomes.